A Study to See Whether Two HIV Vaccines Are Safe and Can Prevent HIV Infection
|ClinicalTrials.gov Identifier: NCT00004579|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections HIV Seronegativity||Biological: gp160 MN/LAI-2 Biological: ALVAC-HIV MN120TMG (vCP205)||Phase 1|
This study consists of 2 parts:
Part A: Dose-escalation protocol using oligomeric gp160MN/LAI-2. Part B: Placebo-controlled, randomized, double-blind (within arm) study of vCP205 priming with gp160MN/LAI-2 boosting.
Volunteers are followed for at least 1 year.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase I, Dose-Ranging Trial of the Pasteur Merieux Connaught (PMC) Oligomeric HIV-1 gp160MN/LAI-2 Vaccine Alone or Primed With Live Recombinant ALVAC-HIV (vCP205) in HIV Seronegative Adults|
|Study Start Date :||April 1998|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004579
|United States, Maryland|
|Walter Reed Army Institute of Research|
|Rockville, Maryland, United States|
|Principal Investigator:||Jerome H. Kim|